^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Non-nucleoside reverse transcriptase inhibitor

    Related drugs:
    9d
    TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (clinicaltrials.gov)
    P3, N=180, Active, not recruiting, Janssen Sciences Ireland UC | Trial completion date: Jan 2032 --> Apr 2026
    Trial completion date
    14d
    IMAdART: Implementation of Long-acting Cabotegravir + Rilpivirine Administration Out of "HIV Units". (clinicaltrials.gov)
    P=N/A, N=90, Completed, Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Trial completion date: Jul 2025 --> Feb 2026 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    15d
    DoraDO: Doravirine Dose Optimisation in Pregnancy (clinicaltrials.gov)
    P4, N=76, Recruiting, University of Liverpool | Trial completion date: Feb 2026 --> Jul 2028 | Trial primary completion date: Nov 2025 --> Jul 2028
    Trial completion date • Trial primary completion date
    17d
    Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066) (clinicaltrials.gov)
    P2, N=84, Recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Mar 2028 --> Nov 2028
    Trial primary completion date
    17d
    Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of nWest Nile Virus Infection in Patients at Risk of Progression - DORICO Trial (2025-521677-14-00)
    P1/2, N=50, Not yet recruiting, Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
    New P1/2 trial
    23d
    Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study. (PubMed, J Antimicrob Chemother)
    A three-day-per-week regimen of efavirenz, emtricitabine, and tenofovir disoproxil fumarate maintained durable long-term viral suppression, while mitigating but not fully preventing toxicities associated with EFV/TDF/FTC. These findings support reduced-exposure antiretroviral therapy and warrant evaluation of similar strategies with modern integrase inhibitor-based regimens.
    Clinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    25d
    “MOCHA” More Options for Children and Adolescents (clinicaltrialsregister.eu)
    P1/2, N=155, National Institute of Allergy and Infectious Diseases, Division of AIDS
    New P1/2 trial
    1m
    Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Yale University | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    Study on the Effect of Antiretroviral Therapy Centered on Enovirine on PD-1 Expression of CD8+ T Cells Induced by Cholesterol (ChiCTR2500113428)
    P4, N=150, Completed, Xixi Hospital of Hangzhou; Xixi Hospital of Hangzhou
    New P4 trial
    |
    efavirenz
    1m
    Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV (clinicaltrials.gov)
    P1, N=26, Completed, University of Texas Southwestern Medical Center | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Dec 2025 | Trial primary completion date: Dec 2025 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date
    1m
    LACRIS: Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study (clinicaltrials.gov)
    P=N/A, N=250, Not yet recruiting, Pomeranian Medical University Szczecin
    New trial • Real-world evidence
    2ms
    ATLAS: Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (clinicaltrials.gov)
    P3, N=618, Active, not recruiting, ViiV Healthcare | Trial completion date: Dec 2025 --> Dec 2029
    Trial completion date • Head-to-Head